This website use cookies and similar technologies to improve the site and to provide customised content and advertising. By using this site, you agree to this use. To learn more, including how to change your cookie settings, please view our Cookie Policy
Xmas Legs Small Present Present
Pocketmags Digital Magazines
Pocketmags Digital Magazines
   You are currently viewing the United Kingdom version of the site.
Would you like to switch to your local site?
Digital Subscriptions > Newsweek International > 24 February 2017 > GETTING BENT OVER BENTGRASS


USDA agrees to not regulate genetically modified grass on the loose in Oregon


MISSION CREEP: Scotts Miracle-Gro has spent millions trying and failing to eradicate creeping bentgrass, which is genetically modified to be resistant to the herbicide Roundup.

THIS IS the story of an Oregon weed that nobody’s high on. In two areas of the state, and in nearby Idaho, a genetically modified (GM), weedy grass has spread beyond fields where it was grown by contractors ailiated with Scotts Miracle-Gro, which developed it beginning in the 1990s in collaboration with Monsanto. Over more than a decade, Scotts has spent millions trying and failing to eradicate the plant, known as creeping bentgrass, which is genetically modified to be resistant to the herbicide Roundup.

Purchase options below
Find the complete article and many more in this issue of Newsweek International - 24 February 2017
If you own the issue, Login to read the full article now.
Single Issue - 24 February 2017
Or 499 points
Annual Digital Subscription
Only £ 0.65 per issue
Or 3299 points
Monthly Digital Subscription
Only £ 0.94 per issue
Or 399 points

View Issues

About Newsweek International

THE WAR ON ALZHEIMER'S This aggressive attempt to prevent Alzheimer’s rather than treating it is the most exciting new development in decades, as well as a radical departure for researchers and the pharmaceutical industry. Traditionally, drug companies have tested their therapies on patients who already have memory loss, trouble thinking and other signs of dementia. It’s been a losing tactic: More than ninety nine percent of all Alzheimer’s drugs have failed tests in the clinic, and the few that have made it to the market only ameliorate some symptoms. No single medicine has been shown to slow the relentless progression of the disease. However this new approach, even partial success an appreciable slowing of brain degeneration could have a big impact, says Dr. Reisa Sperling, a neurologist who directs the Center for Alzheimer’s Researc.